Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

Viridian will webcast a September 8, 2026 conference fireside chat for investors, with replay access available after the event.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that senior management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, at 12:45pm ET.

A live webcast of the fireside chat can be accessed under “Events and Presentations” on the Investors section of the Viridian website at viridiantherapeutics.com. A replay of the webcast will be available following the completion of the event.

About Viridian Therapeutics

Viridian Therapeutics is a biotechnology company dedicated to developing better medicines for patients with autoimmune and rare diseases. Utilizing our expertise in antibody discovery and protein engineering, we aim to build on proven science to develop innovative medicines that address unmet needs and improve patient outcomes.

With an immediate focus in thyroid eye disease (TED), we developed Lumvoa^TM, a full IGF-1R antagonist approved by the U.S. FDA for the treatment of thyroid eye disease. We are also advancing elegrobart, a late-stage investigational subcutaneous therapy designed to further address unmet needs in TED and improve patient convenience. Beyond TED, we are advancing a pipeline of potential best-in-class medicines to address multiple serious autoimmune diseases.

Viridian is headquartered in Waltham, Massachusetts. For more information, please visit www.viridiantherapeutics.com. Follow Viridian on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260902354597/en/

Investors
Greg Rossino
grossino@viridiantherapeutics.com

Source: Viridian Therapeutics, Inc.

Key Terms

igf-1r antagonist medical

A IGF-1R antagonist is a drug or biological agent that blocks the insulin-like growth factor 1 receptor (IGF-1R) on cells, preventing the receptor from receiving growth and survival signals. Because IGF-1R drives cell proliferation and resistance to cell death in some cancers and other diseases, blocking it is a targeted therapeutic strategy; clinical trial outcomes, safety data, and regulatory decisions for such agents can materially affect the value and prospects of companies developing them.

subcutaneous therapy medical

Subcutaneous therapy is a way of giving a medicine by injecting it just under the skin into the fatty layer, usually with a small syringe, pen, or pump. For investors, the delivery method matters because it can make treatments easier to use at home, improve patient adherence, reduce need for clinic visits, and influence manufacturing, pricing and market uptake—factors that affect sales and competitive advantage.